ClinicalTrials.gg
RecruitingNCT07043725Updated Nov 2, 2026

A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer

A Phase 3 interventional study of TQB2102 for injection and Trastuzumab injection and Pertuzumab Injection and Docetaxel Injection and Carboplatin Injection in HER2-positive Breast Cancer, sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.. Recruiting at 77 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 3, Interventional, and Treatment

How we know · 15 judgments · 4 readings being read again

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.
Updated Nov 2, 2026Study contact changed1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
544
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 28 studies in Breast Neoplasms by Sino Biopharmaceutical Limited — 11 open to participants now, 16 under way, 8 of them phase 3. Breast Neoplasms · Sino Biopharmaceutical Limited.

Planned enrollment
3rd of 28
544 · median 138
Started
2025
with 6 others
Phase 3
11 of 28
5 open now
Primary completion
2027-09
later than 10 of 15 live
Registered
25th of 28
by date

Among the 28 studies in Breast Neoplasms by Sino Biopharmaceutical Limited, this one is the 3rd largest by planned enrollment, is one of 7 that started in 2025, is one of 11 in phase 3, reaches primary completion later than 10 of the 15 other live ones, and was the 25th registered.

Breast Neoplasms

14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

11 of the 28 studies in Breast Neoplasms by Sino Biopharmaceutical Limited are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Breast Neoplasms by Sino Biopharmaceutical Limited, or all of them as a file.
02

Study summary

This is a randomized, open, positive drug control, multi center phase III study. Through the evaluation of tpCR, bpCR, ORR, EFS, IDFS, OS, AEs and other indicators, it proves the effectiveness and safety of TQB2102 for injection versus Active Comparator in the neoadjuvant treatment of HER2 positive breast cancer patients.

About 544 HER2 positive early or locally advanced breast cancer patients will be randomly assigned to TQB2102 treatment group (test group) or Docetaxel combined with Carboplatin, Trastuzumab, and Pertuzumab (TCbHP) (Active Comparator) in a 1:1 ratio.

The subjects in the test group will receive 8 cycles of study drug treatment, and the subjects in the control group will receive 6 cycles of study drug treatment, followed by surgery for breast cancer, and disease recurrence visit and survival visit after surgery.

03

Conditions studied

  • HER2-positive Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntarily participate in this study, sign the form, and have good compliance;
  • performance status (ECOG PS) score: 0-1; expected survival >6 months;
  • or cytologically confirmed -positive invasive breast cancer;
  • Hormone receptor (HR) status confirmed;
  • Clinical stage at diagnosis: T2-4 with any N, M0, or any T with N1-3, M0;
  • Agree to undergo breast cancer resection if meeting surgical criteria after therapy;
  • Major organ function is adequate, meeting specific criteria;
  • Must agree to use during the study and for 6 months after study completion; female patients must have a negative serum pregnancy test within 7 days before enrollment and must not be lactating; male subjects must agree to use contraception during the study and for 6 months after study completion

Exclusion criteria

Exclusion Criteria:

  • Stage IV breast cancer or other cases judged by the investigator as unsuitable for radical surgical resection after therapy;
  • Bilateral breast cancer or inflammatory breast cancer;
  • History of invasive breast cancer or ductal carcinoma in situ;
  • Prior anti-tumor therapy for breast cancer, including chemotherapy, endocrine therapy, targeted therapy, radiotherapy, surgery, etc.;
  • Comorbidities and medical history:

    • Other within 5 years or currently;
    • Adverse reactions from prior treatment not recovered to v5.0 grade ≤1;
    • Major surgery, significant traumatic injury within 4 weeks before first dose, or anticipated major surgery during the study, or unhealed wounds/fractures;
    • Conditions affecting intravenous injection or blood sampling;
    • Congenital bleeding or coagulation disorders, or bleeding/coagulation disorders within 28 days before study treatment, or use of aspirin >325 mg/day (maximum antiplatelet dose), dipyridamole, ticlopidine, clopidogrel, or cilostazol within 7 days before study treatment;
    • Arterial/deep venous thrombotic events within 6 months before first dose, e.g., cerebrovascular accident, deep vein thrombosis, pulmonary embolism;
    • Poorly controlled blood pressure (systolic ≥150 mmHg or diastolic ≥100 mmHg);
    • Significant cardiovascular disease, including;
    • Uncontrolled ≥CTCAE grade 2 infection within 14 days before study treatment;
    • History of interstitial lung disease/pneumonitis (non-infectious) requiring treatment, current interstitial lung disease/pneumonitis, or suspected interstitial lung disease/pneumonitis on screening imaging that cannot be ruled out;
  • Tumor-related symptoms and treatment:

    • Prior excisional of primary tumor and/or axillary lymph nodes or sentinel lymph node biopsy before study treatment;
    • Surgery, chemotherapy, radiotherapy, or other anti-tumor therapy within 3 weeks before study treatment ( calculated from last treatment);
    • Prior taxane or carboplatin therapy for any malignancy;
    • Treatment with National Medical Products Administration-approved traditional Chinese medicine with clear anti-tumor indications within 2 weeks before study treatment.
  • Study treatment-related:

    • Severe to monoclonal antibodies;
    • Uncontrolled active disease within 2 weeks before study treatment;
    • Allergy to any study drug or its components/;
    • within 28 days before study treatment, including measles, mumps, rubella, varicella, yellow fever, seasonal flu, Influenza A virus subtype (H1N1) flu, rabies, Bacille Calmette-Guerin vaccine (BCG), and typhoid vaccines.
  • Any condition judged by the investigator to jeopardize subject safety or study completion.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
544 participants (estimated)

Study arms

  • Experimental
    TQB2102 for injection

    6mg/kg TQB2102 for injection, Intravenous infusion, administered every 3 weeks, 21 days as a treatment cycle, 8 cycles.

    Drug: TQB2102 for injection

  • Active comparator
    Trastuzumab injection and Pertuzumab Injection and Docetaxel Injection and Carboplatin Injection

    Trastuzumab injection (The first dose is 8mg/kg, followed by 6mg/kg), Pertuzumab Injection (The first dose is 840, followed by 420mg), Docetaxel Injection (75mg/m2 ) combined with Carboplatin Injection (AUC-6, 800 mg max), Intravenous infusion, administered every 3 weeks, 21 days as a treatment cycle, 6 cycles.

    Drug: Trastuzumab injection and Pertuzumab Injection and Docetaxel Injection and Carboplatin Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Rate of total physiological complete response (tpCR) evaluated by Independent Review Committee (IRC)

    Rate of subjects with no residual invasive cancer in the primary breast lesion and negative regional lymph nodes upon microscopic examination after primary tumor resection, as assessed by IRC.

    Time frame: Up to 26 months after study start

Secondary outcomes

  1. Rate of total physiological complete response (tpCR) evaluated by the investigator

    Rate of subjects with no residual invasive cancer in the primary breast lesion and negative regional lymph nodes upon microscopic examination after primary tumor resection, as assessed by the investigator.

    Time frame: Up to 24 months after study start

  2. Breast pathological complete response (bpCR) evaluated by IRC and the investigator

    Percentage of subjects with no residual invasive cancer in the primary breast lesion upon microscopic examination after primary tumor resection, as assessed by IRC and the investigator.

    Time frame: Up to 26 months after study start

  3. Objective response rate (ORR)

    The percentage of subjects achieving complete response (CR) or partial response (PR) as assessed by the investigator based on the Response Evaluation Criteria In Solid Tumors (RECIST 1.1) .

    Time frame: Up to 22 months after study start

  4. There year Event-free survival (EFS)

    Time from randomization to the first occurrence of any of the following events: ipsilateral or contralateral invasive breast cancer recurrence, regional or distant invasive breast cancer recurrence, or death from any cause.

    Time frame: Up to 50 months after study start

  5. There year Invasive Disease-free survival (IDFS)

    Time from randomization to the first occurrence of any of the following events: ipsilateral or contralateral invasive breast cancer recurrence, regional or distant invasive breast cancer recurrence, or death from any cause.

    Time frame: Up to 50 months after study start

  6. Overall Survival (OS)

    Time from randomization to death due to any cause.

    Time frame: Up to 50 months after study start

  7. Incidence and severity of adverse events (AEs) and serious adverse events (SAEs), and indicators of abnormal laboratory tests

    To evaluate the safety of TQB2102 for Injection compared to TCbHP in the neoadjuvant treatment of HER2 positive early breast cancer, including: the incidence and severity of adverse events (AEs), abnormal laboratory test values, and serious adverse events (SAEs).

    Time frame: From the date of signing the informed consent to 40 days after the last dosing or radical mastectomy for breast cancer or a new anti-tumor treatment, whichever comes first.

  8. Incidence of Anti-drug antibody (ADA) and neutralizing antibodies (NAb)

    Incidence of ADA and Nab

    Time frame: Up to 22 months after study start

07

Study locations

3 of 77 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Sep 2027, 24 months after the start.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 24 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2025
First posted
Jun 29, 2025
StartActual
Sep 15, 2025
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2029
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site removed
Show 1 removed
  • Xinjiang Medical University Cancer Hospital · Ürümqi, China
Nov 2, 2026
Contact
Study contact changed: removed z•••@163.com · •••6668. See the current contact
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    1 site removed
    Show 1 removed
    • Xinjiang Medical University Cancer Hospital · Ürümqi, China
    Contact Study contact changed: removed z•••@163.com · •••6668. See the current contact
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07043725
Responsible party
Sponsor
First posted
Jun 29, 2025
Start date
Sep 15, 2025
Primary completion
Sep 2027 (estimated)
Completion
Sep 2029 (estimated)
Last update
Nov 2, 2026

Study contacts

Zhimin Shao, Doctor
Contact
szm@163.com
13524514617

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102

Start the discussion